A5024023144- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Lesions and Carcinomas
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Health Systems, Economic Evaluations, Quality of Life
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Estrogen and related hormone effects
- COVID-19 and healthcare impacts
- Cancer-related Molecular Pathways
- Click Chemistry and Applications
- Lung Cancer Research Studies
- Family Support in Illness
- Global Cancer Incidence and Screening
- Science, Research, and Medicine
- Breast Implant and Reconstruction
- Cancer survivorship and care
- BRCA gene mutations in cancer
- Computational Drug Discovery Methods
- Bone health and treatments
- Galectins and Cancer Biology
- PARP inhibition in cancer therapy
Ludwig-Maximilians-Universität München
2015-2024
LMU Klinikum
2016-2024
München Klinik
2019-2023
Breast Center
2016-2023
EagleBurgmann (Germany)
2023
Klinik für Frauenheilkunde
2019-2021
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
2019-2021
Ente Ospedaliero Ospedali Galliera
2017
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2017
Institut Curie
2017
The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only few prospective outcome results have been available so far. In the phase III PlanB trial, RS was prospectively used to define subset of patients who received endocrine therapy. We present 3-year data and concordance analysis (among biomarkers/RS).Central tumor bank established from (intermediate high-risk, locally human epidermal growth factor...
Neoadjuvant systemic treatment (NST) elicits a pathologic complete response in 40%-70% of women with breast cancer. These patients may not need surgery as all local tumor has already been eradicated by NST. However, nonsurgical approaches, including imaging or vacuum-assisted biopsy (VAB), were able to accurately identify without residual cancer the axilla. We evaluated feasibility machine learning algorithm (intelligent VAB) exceptional responders NST.We trained, tested, and validated using...
The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality life (QoL) in hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer (MBC) patients receiving palbociclib and an aromatase inhibitor + fulvestrant. CANKADO PRO-React, a European Union-registered medical device, is interactive autonomous...
The side effects of systemic cancer therapy and the lack clinical data on safety efficacy COVID-19 vaccination in patients cause uncertainty among about whether to get vaccinated or not. Here, we evaluated attitude towards with breast gynecological undergoing therapy.Since March 15th, 2021, who received one approved vaccines were routinely interviewed immediate late effects. Clinical parameters such as current therapy, time interval between administration vaccination, changes schedule due...
•This was an international, multicenter analysis including 691 patients with metastatic TNBC.•The frequency of HER2-low 32.0% (95% CI 28.5% to 35.5%).•Similar frequencies were seen in metastases (29.8%) and primary tumors (33.4%; P = 0.324).•There no statistically different OS between HER2-0 TNBC (HR 1.00; 0.969).•There significant impact on multivariable 0.95; 0.545). BackgroundTriple-negative breast cancer (TNBC) is associated poor prognosis, new treatment options are urgently needed....
1008 Background: The multicenter, randomized phase IV Intergroup PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based ePRO assessment on quality life (QoL) in HR+/HER2- locally advanced or metastatic breast cancer (MBC) patients (pts) treated with palbociclib (P) and an aromatase inhibitor P+fulvestrant. CANKADO PRO-React, EU- registered medical device, is autonomous application reacting to changes pt self- reported QoL. Methods: Between 2017 2021, 499 pts (median age 59y) from...
Abstract Background Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor 2 negative (HER2 −) MBC, addition targeted oral agents such as everolimus or a cycline-dependent kinase 4/6 (CDK 4/6) inhibitor (e.g., palbociclib, ribociclib, abemaciclib) to endocrine substantially prolongs progression-free survival the case CDK 4/6i also overall survival. However, prerequisite is...
Abstract Background: Both the Recurrence Score® (RS) multi-gene assay and invasion factors uPA/PAI-1 are recommended by guidelines (ASCO, AGO) for decision support regarding adjuvant chemotherapy (cht) in patients with early breast cancer (BC). In EC-DOC trial, we previously suggested central grade 3 high Ki-67 levels as independent predictive markers enhanced benefit of taxane-based cht intermediate risk BC. Here, present final WSG-Plan B trial correlation analysis these assessment tools....
Abstract Background Breast cancer patients with residual disease after neoadjuvant systemic treatment (NAST) have a worse prognosis compared those achieving pathologic complete response (pCR). Earlier identification of these might allow timely, extended strategies. We explored the feasibility vacuum-assisted biopsy (VAB) NAST to identify (ypT+ or ypN+) prior surgery. Methods used data from multicenter trial, collected at 21 study sites (NCT02948764). The trial included women cT1-3, cN0/+...
<b><i>Background:</i></b> This study aimed to identify the association of local surgery primary tumor in metastatic breast cancer (MBC) patients with overall survival (OS) and prognostic factors. <b><i>Patients Methods:</i></b> Patients MBC (1990-2006) were included our retrospective analysis (n = 236). 83.1% had for tumor. OS was evaluated using Kaplan-Meier estimates. Predictive factors determined....
2083 Background: PreCycle (NCT03220178), a multicenter, randomized phase IV Intergroup trial evaluates the impact of ePRO assessment on quality life (QoL) in HR+/HER2- locally advanced or metastatic breast cancer patients (pts) treated by palbociclib (P) and an aromatase inhibitor P+fulvestrant. Pts willing to use web/APP-eHealth solution CANKADO are eligible. Patients (2:1, stratified therapy line) active (CANKADO PRO-React) inactive inform arm. Primary endpoint is time deterioration (TTD)...
10594 Background: Both the recurrence score (RS) multi-gene assay and invasion factors uPA/PAI-1 are included in guidelines (ASCO, AGO) for decision support regarding adjuvant chemotherapy early breast cancer (BC). Here we present first preplanned WSG-Plan B trial correlation analysis of RS, uPA/PAI-1, molecular subtypes by protein expression. Methods: Plan (n=2,448) is evaluating anthracycline-free (6x TC) vs. 4xEC-4xDOC HER2-negative BC. RS used as selection criterion or hormonal therapy...
Molecular factors that drive metastasis in premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2−), early breast cancer (EBC) are largely unknown. To identify markers/signatures contributing to metastasis, we analyzed molecular changes tumors from who developed (M1) and did not (M0). Ninety-seven HR+/HER2− EBC were included (M1, n = 48, median distant metastasis-free survival (DMFS): 54 (7–184) months; M0, 49, follow-up: 149 (121–191)...
This study evaluates interventions offered to young breast cancer (BC) patients, including fertility preservation, genetic testing, and counseling for parenthood concerns, analyzes the effect of BC on biographical issues.Women who were diagnosed with at age 18-40 years underwent treatment Breast Center, Ludwig-Maximilian University (LMU) in Munich between 2006 2013, eligible this study. Patients received a self-developed questionnaire which covered following topics: family planning, concerns...
Introduction: The interdisciplinary empowerment seminar aims to familiarize patients and informal caregivers (ICs) with supportive measures, focusing on understanding disease, therapy, side effect management. Methods: seminar, conducted in two courses over 1-month intervals prior chemotherapy, included lectures, materials, Q A sessions, individual discussions experts nutrition, exercise, psycho-oncology, complementary medicine. Evaluation is based a self-developed questionnaire...
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are involved in various immune cell-mediated diseases. Their role cancer is poorly investigated, and research focusses on Siglec-expression cells interacting with tumor cells. This study evaluates the of Siglec-8 breast (BC). expression was analyzed immunohistochemically 235 primary BC cases correlated clinical pathological parameters outcome. Cell culture experiments were performed cell lines. expressed 215 lowest triple-negative BC....